Exosome-based Vaccine Solution

Creative Biolabs offers a one-stop service for Exosome Vaccine Design and development. Utilizing advanced isolation, loading, and modification technologies, we specialize in constructing highly efficient, targeted novel exosome vectors for the development of prophylactic and therapeutic vaccines across areas like cancer and infectious diseases. Leveraging years of professional experience and cutting-edge platforms, we are dedicated to accelerating our clients' projects from concept verification through preclinical studies.

Concepts and Challenges in Exosome Vaccine Design

The exosome vaccine utilizes naturally secreted nanovesicles (exosomes) as an antigen delivery system. due to their excellent biocompatibility, low immunogenicity, and inherent targeting capabilities, exosomes are an ideal vector for next-generation vaccine design. The core concept of exosome vaccine design is to harness the exosome's natural adjuvant effect (activating antigen-presenting cells via surface molecules to induce a potent immune response) and its advantages in transmembane delivery (as nanoparticles, efficiently crossing biological barriers to deliver antigens or nucleic acid drugs to target cells).

Key Issues to Address in Exosome-based Vaccine Development:

Large-scale Preparation and Purification

How to efficiently, highly purely, and reproducibly isolate and produce exosome vectors for clinical application.

Payload Loading Efficiency

How to improve the loading efficiency and stability of exogenous antigens or drug molecules (e.g., mRNA) into the exosome interior, ensuring their activity upon in vivo delivery.

Targeting Optimization

How to surface-engineer the exosome to enhance its targeting capability towards specific immune cells or disease sites, thereby minimizing off-target effects.

Creative Biolabs Exosome Vaccine Development Services

We are dedicated to solving the core challenges—efficiency, purity, and functionality—that clients face in exosome vaccine design, accelerating your innovative R&D process.

Core Problems We Help Clients Solve:

Inefficient Antigen/Nucleic Acid Loading

We use proprietary ultrasonic, electroporation, and active targeting modification techniques to overcome the low efficiency of traditional loading methods.

Exosome Purity and Batch Consistency

Utilizing optimized ultracentrifugation combined with chromatographic separation (e.g., FPLC/SEC) methods, we provide high-purity, highly consistent preclinical-grade exosomes between batches.

Specific Targeted Delivery Needs

We offer surface engineering modifications, equipping exosomes with specific peptides, antibodies, or aptamers to achieve precise targeting of tumors or specific immune cells.

Detailed Services We Provide:

Detailed Services (Services in Exosome-based Vaccine Design)	Description
Exosome Isolation and Characterization Services	Utilizing technologies such as ultrafiltration, density gradient centrifugation, and immunomagnetic bead capture for highly efficient separation of exosomes from cell culture supernatants or biological fluids. Comprehensive characterization is performed, including NTA, TEM, and WB (e.g., CD9/CD63/TSG101).
Antigen/Drug Active Loading Optimization	Offering multiple loading strategies, including electroporation, sonoporation, Saponin treatment, and receptor-based loading, to achieve high-efficiency encapsulation of payloads like protein antigens, mRNA, and siRNA.
Exosome Surface Engineering Design	Modifying the exosome surface through chemical conjugation or genetic engineering of parent cells to introduce targeting peptides (e.g., RGD), antibody fragments (e.g., scFv), or Toll-like Receptor (TLR) agonists, thereby enhancing immunogenicity and targeting.
Immunogenicity Assessment and Verification	Evaluation of the Exosome Vaccine's immune response in vitro (e.g., DC cell maturation, T cell proliferation) and in vivo (mouse models), including cell-mediated immunity (CTL) and humoral immunity (antibody titers).

Core Platforms Supporting Exosome Vaccine Design

Structure, workflow or performance data of high-efficiency exosome isolation platform

High-Efficiency Isolation Platform

qEV Size Exclusion Chromatography (SEC): Used for high-purity separation and fractionation of exosomes.
Immunoaffinity Capture System: Based on specific surface markers (e.g., CD9, CD63) for specific capture, ensuring high purity.

Method, efficiency or result of payload loading into exosomes for vaccine preparation.

Payload Loading Platform

Exo-Pulse Electroporation System: Optimized electroporation system for exosomes, used for high-efficiency nucleic acid (mRNA/miRNA) loading.
Acoustic Focussing Technology: Utilizing acoustic focusing to achieve gentle and high-throughput loading.

Exosome Surface Modification and Engineering

"Click" Chemistry Modification: Enables precise and stable conjugation of targeting ligands or immune adjuvants to the exosome surface.
Parent Cell Genetic Engineering: Modification of exosome parent cells to express exosomes carrying specific antigens and targeting modules.

Exosome Vaccine Design and Development Process

Target Identification and Antigen Design

Based on the disease type (e.g., tumor neoantigens, viral antigens), strong immunogenic targets are determined, and appropriate antigen formats (peptide, protein, or mRNA) are designed.

Exosome Source Selection and Preparation

Selection of suitable exosome parent cells (e.g., DC cells, Mesenchymal Stem Cells, or engineered cells), followed by large-scale culture and high-purity exosome isolation.

Payload Loading and Optimization

Loading the designed antigen or nucleic acid molecules into the exosomes, and quantitatively verifying loading efficiency and stability using methods like ELISA and qPCR.

Surface Functionalization Modification (Optional)

Using chemical or biological engineering methods to modify the exosome surface, enhancing targeting or adjuvant function.

Immunogenicity and Functional Verification

Verification of the Exosome Vaccine's ability to activate Antigen-Presenting Cells (APCs) in vitro, induce Cytotoxic T Lymphocytes (CTLs), and stimulate a humoral immune response. Comprehensive assessment of the vaccine's safety, immunogenicity (antibody titers, T cell response), and protective/therapeutic efficacy is then conducted in vivo in immunocompetent animal models.

Process Scale-Up and Quality Control (QC)

Establishing a standardized, reproducible production and QC process to lay the foundation for preclinical and clinical translation.

Partner with Creative Biolabs Now!

Creative Biolabs' Edge in Exosome Vaccine Design

One-Stop, Full-Chain Service

Covering the entire process from target discovery, exosome preparation, loading modification, to in vitro and in vivo evaluation, eliminating the need for multi-party collaboration, saving time and cost.

Dual Expertise in Nucleic Acid and Protein Loading

Possessing industry-leading mRNA/siRNA nucleic acid loading technology, as well as stable encapsulation solutions for complex protein antigens.

Professional Targeting Engineering Experience

Our team of senior experts has extensive experience in designing exosome surface targeting molecules, enabling precise delivery to the tumor microenvironment or specific immune organs.

Strict Biosafety Standards

All preparation processes adhere to rigorous quality control standards, ensuring the low toxicity and high safety of the final exosome vaccine product.

Summary of advantages in the design of exosome-based vaccine.

Client Testimonials for Exosome Vaccine Services

"The expert team at Creative Biolabs is top-tier in exosome mRNA vaccine loading technology. They not only helped us solve the challenge of nucleic acid degradation but also tripled the loading efficiency, greatly accelerating our preclinical tumor vaccine research. Highly recommend their exosome vaccine design service!"

— Dr. Chen M.,

Biotech Start-up CEO

"We hit a bottleneck while trying to construct engineered exosomes against a specific neoantigen. Creative Biolabs provided a very innovative surface modification protocol that successfully enhanced the exosome's targeting capability. Their rapid response and professional support greatly impressed us."

— Prof. A. Rossi,

University Research Lead

"We chose Creative Biolabs for the in vitro immunogenicity assessment of our exosome vaccine. The detailed data and professional analysis provided far exceeded our expectations, especially demonstrating the sensitivity and reliability of their platform in T cell activation assays. This provided a solid foundation for our next stage of in vivo trials."

— Mr. L. Kim,

Pharma R&D Manager

Case Study

Exosome-Based Multivalent Vaccine for SARS-CoV-2

Background

Current SARS-CoV-2 vaccines have limitations: mRNA vaccines need ultralow-temperature storage and have limited variant coverage; protein-based ones require adjuvants and more time to develop. The challenge was to create a fast, low-dose vaccine with potent, broad immunity.

Solution

Capricor Therapeutics engineered exosomes (StealthX platform) to express SARS-CoV-2 delta spike (STX-S) and nucleocapsid (STX-N) on the surface. They tested single (STX-S/STX-N) and combined (STX-S1N) vaccines in mice and rabbits, using nanogram doses without adjuvants.

Results

STX-S1N induced strong humoral (high neutralizing antibodies cross-reacting with delta/omicron) and cellular (robust CD4+/CD8+ T-cell) responses. It used 100-fold less protein than traditional vaccines, with no antigen competition, supporting its potential for next-gen broad-spectrum vaccines.

Experimental data showing that STX-S and STX-N exosomes induce strong immunization without an adjuvant.

STX-S and STX-N Exosomes Induce Strong Immunization Without an Adjuvant.
Cacciottolo, Mafalda, et al. "Exosome-based multivalent vaccine: achieving potent immunization, broadened reactivity, and strong T-cell responses with nanograms of proteins." Microbiology Spectrum 11.3 (2023): e00503-23. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1128/spectrum.00503-23.

Frequently Asked Questions about Exosome Vaccine Services

What is the best cell source for Exosome Vaccine Design?

The optimal source depends on the application goal. Dendritic Cell (DC)-derived exosomes are naturally highly immunogenic, suitable for immunotherapy; Mesenchymal Stem Cell (MSC)-derived exosomes have low immunogenicity, suitable for drug delivery. We provide customized recommendations based on your project needs.

How do you ensure the stability of exogenous nucleic acids (e.g., mRNA) after loading?

We use loading technologies optimized for exosomes (such as Exo-Pulse electroporation) combined with specific stabilizer formulations. This ensures the mRNA is undamaged during the loading process and maximizes its resistance to nuclease degradation during in vivo circulation.

What are the main advantages of an Exosome Vaccine compared to traditional Lipid Nanoparticle (LNP) vaccines?

Exosome Vaccines have natural biocompatibility and extremely low toxicity. Their surfaces naturally carry various proteins, acting as intrinsic immune adjuvants without needing external additions, and their inherent targeting capabilities are superior to traditional LNP delivery systems.

Does Payload Loading Affect the Natural Targeting or Bioactivity of Exosomes?

We employ gentle loading techniques and surface modification methods designed to minimize the impact on the surface protein structure and natural targeting capability of the Exosome Vaccine. Post-loading, we perform Zeta potential and NTA size analysis, along with in vitro target cell uptake assays, to ensure key biological characteristics are preserved.

Can you design surface modifications for our Exosome Vaccine to target specific tissues or cells?

Yes. We offer comprehensive surface engineering services, including but not limited to functionalization using aptamers, specific peptides, or antibody fragments, to achieve precise targeting of tumor cells, endothelial cells, or specific immune cells.

Embark on Your Exosome Vaccine Exploration Journey

If you are in pursuit of breakthrough approaches for exosome-based vaccine development or aiming to overcome challenges in your exosome vaccine research and accelerate project progress, please reach out to us.

Featured Resources

Reference image of vaccine-resources-1, containing materials relevant to vaccine research and development.

Download Resources

Visual of vaccine-literature-1, representing academic or technical literature focused on vaccine studies.